PFIZER RECEIVES EUROPEAN APPROVAL TO MARKET AROMASIN(R)

Pfizer Inc said today that it has received European Mutual Recognition Procedure (MRP) approval to market Aromasin(R) (exemestane tablets) for a new indication, adjuvant treatment of estrogen receptor positive invasive early breast cancer following two-to-three years of initial adjuvant tamoxifen therapy in postmenopausal women. Aromasin is a hormonal therapy, used to treat women with breast cancers that depend on a hormone, specifically estrogen, for growth and survival. An estimated two-thirds of breast cancer cases are estrogen-dependent.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/09-13-2005/0004106076&EDATE=)